Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Daniel Arie Haber, M.D., PH.D.

TitleKurt J. Isselbacher/Peter D. Schwartz Professor of Oncology
InstitutionMassachusetts General Hospital
DepartmentMedicine
AddressMassachusetts General Hospital
MGH Cancer Center, CNY7
149 13th Street
Charlestown MA 02129
Phone617/726-7805
Fax617/724-6919

 Mentoring 
 completed student projects
An shRNA Screen for Regulators of Epithelial-to-Mesenchymal Transition
Summer, 05/29/08 - 08/22/08

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Javaid S, Zhang J, Anderssen E, Black JC, Wittner BS, Tajima K, Ting DT, Smolen GA, Zubrowski M, Desai R, Maheswaran S, Ramaswamy S, Whetstine JR, Haber DA. Dynamic Chromatin Modification Sustains Epithelial-Mesenchymal Transition following Inducible Expression of Snail-1. Cell Rep. 2013 Dec 26; 5(6):1679-89.
    View in: PubMed
  2. Liu M, Roth A, Yu M, Morris R, Bersani F, Rivera MN, Lu J, Shioda T, Vasudevan S, Ramaswamy S, Maheswaran S, Diederichs S, Haber DA. The IGF2 intronic miR-483 selectively enhances transcription from IGF2 fetal promoters and enhances tumorigenesis. Genes Dev. 2013 Dec 1; 27(23):2543-8.
    View in: PubMed
  3. Akhavanfard S, Vargas SO, Han M, Nitta M, Chang CB, Le LP, Fazlollahi L, Nguyen Q, Ma Y, Cosper A, Dias-Santagata D, Han JY, Bergethon K, Borger DR, Ellisen LW, Pomeroy SL, Haber DA, Iafrate AJ, Rivera MN. Inactivation of the tumor suppressor WTX in a subset of pediatric tumors. Genes Chromosomes Cancer. 2014 Jan; 53(1):67-77.
    View in: PubMed
  4. Corcoran RB, Rothenberg SM, Hata AN, Faber AC, Piris A, Nazarian RM, Brown RD, Godfrey JT, Winokur D, Walsh J, Mino-Kenudson M, Maheswaran S, Settleman J, Wargo JA, Flaherty KT, Haber DA, Engelman JA. TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF-Mutant Melanoma. Sci Transl Med. 2013 Jul 31; 5(196):196ra98.
    View in: PubMed
  5. Horning SJ, Haber DA, Selig WK, Ivy SP, Roberts SA, Allen JD, Sigal EV, Sawyers CL. Developing standards for breakthrough therapy designation in oncology. Clin Cancer Res. 2013 Aug 15; 19(16):4297-304.
    View in: PubMed
  6. Lee RJ, Saylor PJ, Dror Michaelson M, Michael Rothenberg S, Smas ME, Miyamoto DT, Gurski CA, Xie W, Maheswaran S, Haber DA, Goldin JG, Smith MR. A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clin Cancer Res. 2013 Jun 1; 19(11):3088-94.
    View in: PubMed
  7. Ozkumur E, Shah AM, Ciciliano JC, Emmink BL, Miyamoto DT, Brachtel E, Yu M, Chen PI, Morgan B, Trautwein J, Kimura A, Sengupta S, Stott SL, Karabacak NM, Barber TA, Walsh JR, Smith K, Spuhler PS, Sullivan JP, Lee RJ, Ting DT, Luo X, Shaw AT, Bardia A, Sequist LV, Louis DN, Maheswaran S, Kapur R, Haber DA, Toner M. Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med. 2013 Apr 3; 5(179):179ra47.
    View in: PubMed
  8. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, Concannon KF, Donaldson MC, Sequist LV, Brachtel E, Sgroi D, Baselga J, Ramaswamy S, Toner M, Haber DA, Maheswaran S. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013 Feb 1; 339(6119):580-4.
    View in: PubMed
  9. Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, Bindal N, Beare D, Smith JA, Thompson IR, Ramaswamy S, Futreal PA, Haber DA, Stratton MR, Benes C, McDermott U, Garnett MJ. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013 Jan 1; 41(D1):D955-61.
    View in: PubMed
  10. Mitra D, Luo X, Morgan A, Wang J, Hoang MP, Lo J, Guerrero CR, Lennerz JK, Mihm MC, Wargo JA, Robinson KC, Devi SP, Vanover JC, D'Orazio JA, McMahon M, Bosenberg MW, Haigis KM, Haber DA, Wang Y, Fisher DE. An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature. 2012 Nov 15; 491(7424):449-53.
    View in: PubMed
  11. Miyamoto DT, Lee RJ, Stott SL, Ting DT, Wittner BS, Ulman M, Smas ME, Lord JB, Brannigan BW, Trautwein J, Bander NH, Wu CL, Sequist LV, Smith MR, Ramaswamy S, Toner M, Maheswaran S, Haber DA. Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov. 2012 Nov; 2(11):995-1003.
    View in: PubMed
  12. Yu M, Ting DT, Stott SL, Wittner BS, Ozsolak F, Paul S, Ciciliano JC, Smas ME, Winokur D, Gilman AJ, Ulman MJ, Xega K, Contino G, Alagesan B, Brannigan BW, Milos PM, Ryan DP, Sequist LV, Bardeesy N, Ramaswamy S, Toner M, Maheswaran S, Haber DA. RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature. 2012 Jul 26; 487(7408):510-3.
    View in: PubMed
  13. Shah AM, Yu M, Nakamura Z, Ciciliano J, Ulman M, Kotz K, Stott SL, Maheswaran S, Haber DA, Toner M. Biopolymer system for cell recovery from microfluidic cell capture devices. Anal Chem. 2012 Apr 17; 84(8):3682-8.
    View in: PubMed
  14. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J, Liu Q, Iorio F, Surdez D, Chen L, Milano RJ, Bignell GR, Tam AT, Davies H, Stevenson JA, Barthorpe S, Lutz SR, Kogera F, Lawrence K, McLaren-Douglas A, Mitropoulos X, Mironenko T, Thi H, Richardson L, Zhou W, Jewitt F, Zhang T, O'Brien P, Boisvert JL, Price S, Hur W, Yang W, Deng X, Butler A, Choi HG, Chang JW, Baselga J, Stamenkovic I, Engelman JA, Sharma SV, Delattre O, Saez-Rodriguez J, Gray NS, Settleman J, Futreal PA, Haber DA, Stratton MR, Ramaswamy S, McDermott U, Benes CH. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012 Mar 29; 483(7391):570-5.
    View in: PubMed
  15. Singh A, Sweeney MF, Yu M, Burger A, Greninger P, Benes C, Haber DA, Settleman J. TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. Cell. 2012 Feb 17; 148(4):639-50.
    View in: PubMed
  16. Kim WJ, Rivera MN, Coffman EJ, Haber DA. The WTX tumor suppressor enhances p53 acetylation by CBP/p300. Mol Cell. 2012 Mar 9; 45(5):587-97.
    View in: PubMed
  17. Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Bergethon K, Lauwers GY, Christensen JG, Wilner KD, Haber DA, Salgia R, Bang YJ, Clark JW, Solomon BJ, Iafrate AJ. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol. 2011 Dec 20; 29(36):4803-10.
    View in: PubMed
  18. Chiba N, Comaills V, Shiotani B, Takahashi F, Shimada T, Tajima K, Winokur D, Hayashida T, Willers H, Brachtel E, Vivanco MD, Haber DA, Zou L, Maheswaran S. Homeobox B9 induces epithelial-to-mesenchymal transition-associated radioresistance by accelerating DNA damage responses. Proc Natl Acad Sci U S A. 2012 Feb 21; 109(8):2760-5.
    View in: PubMed
  19. Moisan A, Rivera MN, Lotinun S, Akhavanfard S, Coffman EJ, Cook EB, Stoykova S, Mukherjee S, Schoonmaker JA, Burger A, Kim WJ, Kronenberg HM, Baron R, Haber DA, Bardeesy N. The WTX tumor suppressor regulates mesenchymal progenitor cell fate specification. Dev Cell. 2011 May 17; 20(5):583-96.
    View in: PubMed
  20. Haber DA, Gray NS, Baselga J. The evolving war on cancer. Cell. 2011 Apr 1; 145(1):19-24.
    View in: PubMed
  21. Yu M, Stott S, Toner M, Maheswaran S, Haber DA. Circulating tumor cells: approaches to isolation and characterization. J Cell Biol. 2011 Feb 7; 192(3):373-82.
    View in: PubMed
  22. Ting DT, Lipson D, Paul S, Brannigan BW, Akhavanfard S, Coffman EJ, Contino G, Deshpande V, Iafrate AJ, Letovsky S, Rivera MN, Bardeesy N, Maheswaran S, Haber DA. Aberrant overexpression of satellite repeats in pancreatic and other epithelial cancers. Science. 2011 Feb 4; 331(6017):593-6.
    View in: PubMed
  23. Smolen GA, Zhang J, Zubrowski MJ, Edelman EJ, Luo B, Yu M, Ng LW, Scherber CM, Schott BJ, Ramaswamy S, Irimia D, Root DE, Haber DA. A genome-wide RNAi screen identifies multiple RSK-dependent regulators of cell migration. Genes Dev. 2010 Dec 1; 24(23):2654-65.
    View in: PubMed
  24. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010 Oct 28; 363(18):1693-703.
    View in: PubMed
  25. Stott SL, Hsu CH, Tsukrov DI, Yu M, Miyamoto DT, Waltman BA, Rothenberg SM, Shah AM, Smas ME, Korir GK, Floyd FP, Gilman AJ, Lord JB, Winokur D, Springer S, Irimia D, Nagrath S, Sequist LV, Lee RJ, Isselbacher KJ, Maheswaran S, Haber DA, Toner M. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A. 2010 Oct 26; 107(43):18392-7.
    View in: PubMed
  26. Ozsolak F, Ting DT, Wittner BS, Brannigan BW, Paul S, Bardeesy N, Ramaswamy S, Milos PM, Haber DA. Amplification-free digital gene expression profiling from minute cell quantities. Nat Methods. 2010 Aug; 7(8):619-21.
    View in: PubMed
  27. Wells J, Rivera MN, Kim WJ, Starbuck K, Haber DA. The predominant WT1 isoform (+KTS) encodes a DNA-binding protein targeting the planar cell polarity gene Scribble in renal podocytes. Mol Cancer Res. 2010 Jul; 8(7):975-85.
    View in: PubMed
  28. Aiden AP, Rivera MN, Rheinbay E, Ku M, Coffman EJ, Truong TT, Vargas SO, Lander ES, Haber DA, Bernstein BE. Wilms tumor chromatin profiles highlight stem cell properties and a renal developmental network. Cell Stem Cell. 2010 Jun 4; 6(6):591-602.
    View in: PubMed
  29. Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, Boisvert SL, Stubbs H, McDermott U, Settleman J, Kwak EL, Clark JW, Isakoff SJ, Sequist LV, Engelman JA, Lynch TJ, Haber DA, Louis DN, Ellisen LW, Borger DR, Iafrate AJ. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med. 2010 May; 2(5):146-58.
    View in: PubMed
  30. Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L, Inserra EJ, Ulman M, Springer S, Nakamura Z, Moore AL, Tsukrov DI, Kempner ME, Dahl DM, Wu CL, Iafrate AJ, Smith MR, Tompkins RG, Sequist LV, Toner M, Haber DA, Maheswaran S. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med. 2010 Mar 31; 2(25):25ra23.
    View in: PubMed
  31. Sharma SV, Haber DA, Settleman J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer. 2010 Apr; 10(4):241-53.
    View in: PubMed
  32. Rothenberg SM, Mohapatra G, Rivera MN, Winokur D, Greninger P, Nitta M, Sadow PM, Sooriyakumar G, Brannigan BW, Ulman MJ, Perera RM, Wang R, Tam A, Ma XJ, Erlander M, Sgroi DC, Rocco JW, Lingen MW, Cohen EE, Louis DN, Settleman J, Haber DA. A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers. Cancer Res. 2010 Mar 15; 70(6):2158-64.
    View in: PubMed
  33. Maheswaran S, Haber DA. Circulating tumor cells: a window into cancer biology and metastasis. Curr Opin Genet Dev. 2010 Feb; 20(1):96-9.
    View in: PubMed
  34. Zhang J, Ji JY, Yu M, Overholtzer M, Smolen GA, Wang R, Brugge JS, Dyson NJ, Haber DA. YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway. Nat Cell Biol. 2009 Dec; 11(12):1444-50.
    View in: PubMed
  35. Zhang J, Song YH, Brannigan BW, Wahrer DC, Schiripo TA, Harris PL, Haserlat SM, Ulkus LE, Shannon KM, Garber JE, Freedman ML, Henderson BE, Zou L, Sgroi DC, Haber DA, Bell DW. Prevalence and functional analysis of sequence variants in the ATR checkpoint mediator Claspin. Mol Cancer Res. 2009 Sep; 7(9):1510-6.
    View in: PubMed
  36. Yu M, Smolen GA, Zhang J, Wittner B, Schott BJ, Brachtel E, Ramaswamy S, Maheswaran S, Haber DA. A developmentally regulated inducer of EMT, LBX1, contributes to breast cancer progression. Genes Dev. 2009 Aug 1; 23(15):1737-42.
    View in: PubMed
  37. Rivera MN, Kim WJ, Wells J, Stone A, Burger A, Coffman EJ, Zhang J, Haber DA. The tumor suppressor WTX shuttles to the nucleus and modulates WT1 activity. Proc Natl Acad Sci U S A. 2009 May 19; 106(20):8338-43.
    View in: PubMed
  38. McDermott U, Ames RY, Iafrate AJ, Maheswaran S, Stubbs H, Greninger P, McCutcheon K, Milano R, Tam A, Lee DY, Lucien L, Brannigan BW, Ulkus LE, Ma XJ, Erlander MG, Haber DA, Sharma SV, Settleman J. Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors. Cancer Res. 2009 May 1; 69(9):3937-46.
    View in: PubMed
  39. Sequist LV, Nagrath S, Toner M, Haber DA, Lynch TJ. The CTC-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients. J Thorac Oncol. 2009 Mar; 4(3):281-3.
    View in: PubMed
  40. Chin TM, Quinlan MP, Singh A, Sequist LV, Lynch TJ, Haber DA, Sharma SV, Settleman J. Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment. Clin Cancer Res. 2008 Nov 1; 14(21):6867-76.
    View in: PubMed
  41. Kim S, Mohapatra G, Haber DA. In vitro phosphorylation of BRCA2 by the checkpoint kinase CHEK2. Br J Cancer. 2008 Oct 21; 99(8):1302-6.
    View in: PubMed
  42. Rothenberg SM, Engelman JA, Le S, Riese DJ, Haber DA, Settleman J. Modeling oncogene addiction using RNA interference. Proc Natl Acad Sci U S A. 2008 Aug 26; 105(34):12480-4.
    View in: PubMed
  43. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, Inserra E, Diederichs S, Iafrate AJ, Bell DW, Digumarthy S, Muzikansky A, Irimia D, Settleman J, Tompkins RG, Lynch TJ, Toner M, Haber DA. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 2008 Jul 24; 359(4):366-77.
    View in: PubMed
  44. Bell DW, Brannigan BW, Matsuo K, Finkelstein DM, Sordella R, Settleman J, Mitsudomi T, Haber DA. Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms. Clin Cancer Res. 2008 Jul 1; 14(13):4079-84.
    View in: PubMed
  45. Diederichs S, Jung S, Rothenberg SM, Smolen GA, Mlody BG, Haber DA. Coexpression of Argonaute-2 enhances RNA interference toward perfect match binding sites. Proc Natl Acad Sci U S A. 2008 Jul 8; 105(27):9284-9.
    View in: PubMed
  46. Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE, Dias-Santagata D, Stubbs H, Lee DY, Singh A, Drew L, Haber DA, Settleman J. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 2008 Jun 15; 68(12):4853-61.
    View in: PubMed
  47. Li H, Smolen GA, Beers LF, Xia L, Gerald W, Wang J, Haber DA, Lee SB. Adenosine transporter ENT4 is a direct target of EWS/WT1 translocation product and is highly expressed in desmoplastic small round cell tumor. PLoS One. 2008; 3(6):e2353.
    View in: PubMed
  48. Wittner BS, Sgroi DC, Ryan PD, Bruinsma TJ, Glas AM, Male A, Dahiya S, Habin K, Bernards R, Haber DA, Van't Veer LJ, Ramaswamy S. Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort. Clin Cancer Res. 2008 May 15; 14(10):2988-93.
    View in: PubMed
  49. Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol. 2008 May 20; 26(15):2442-9.
    View in: PubMed
  50. McDermott U, Iafrate AJ, Gray NS, Shioda T, Classon M, Maheswaran S, Zhou W, Choi HG, Smith SL, Dowell L, Ulkus LE, Kuhlmann G, Greninger P, Christensen JG, Haber DA, Settleman J. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res. 2008 May 1; 68(9):3389-95.
    View in: PubMed
  51. Zhang J, Smolen GA, Haber DA. Negative regulation of YAP by LATS1 underscores evolutionary conservation of the Drosophila Hippo pathway. Cancer Res. 2008 Apr 15; 68(8):2789-94.
    View in: PubMed
  52. Godin-Heymann N, Ulkus L, Brannigan BW, McDermott U, Lamb J, Maheswaran S, Settleman J, Haber DA. The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Mol Cancer Ther. 2008 Apr; 7(4):874-9.
    View in: PubMed
  53. Kim WJ, Okimoto RA, Purton LE, Goodwin M, Haserlat SM, Dayyani F, Sweetser DA, McClatchey AI, Bernard OA, Look AT, Bell DW, Scadden DT, Haber DA. Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias. Blood. 2008 May 1; 111(9):4716-22.
    View in: PubMed
  54. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky A, Ryan P, Balis UJ, Tompkins RG, Haber DA, Toner M. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007 Dec 20; 450(7173):1235-9.
    View in: PubMed
  55. Bell DW, Kim SH, Godwin AK, Schiripo TA, Harris PL, Haserlat SM, Wahrer DC, Haiman CA, Daly MB, Niendorf KB, Smith MR, Sgroi DC, Garber JE, Olopade OI, Le Marchand L, Henderson BE, Altshuler D, Haber DA, Freedman ML. Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Int J Cancer. 2007 Dec 15; 121(12):2661-7.
    View in: PubMed
  56. Diederichs S, Haber DA. Dual role for argonautes in microRNA processing and posttranscriptional regulation of microRNA expression. Cell. 2007 Dec 14; 131(6):1097-108.
    View in: PubMed
  57. McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, Archibald H, Raudales R, Tam A, Lee D, Rothenberg SM, Supko JG, Sordella R, Ulkus LE, Iafrate AJ, Maheswaran S, Njauw CN, Tsao H, Drew L, Hanke JH, Ma XJ, Erlander MG, Gray NS, Haber DA, Settleman J. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A. 2007 Dec 11; 104(50):19936-41.
    View in: PubMed
  58. Han M, Rivera MN, Batten JM, Haber DA, Dal Cin P, Iafrate AJ. Wilms' tumor with an apparently balanced translocation t(X;18) resulting in deletion of the WTX gene. Genes Chromosomes Cancer. 2007 Oct; 46(10):909-13.
    View in: PubMed
  59. Smolen GA, Schott BJ, Stewart RA, Diederichs S, Muir B, Provencher HL, Look AT, Sgroi DC, Peterson RT, Haber DA. A Rap GTPase interactor, RADIL, mediates migration of neural crest precursors. Genes Dev. 2007 Sep 1; 21(17):2131-6.
    View in: PubMed
  60. Godin-Heymann N, Bryant I, Rivera MN, Ulkus L, Bell DW, Riese DJ, Settleman J, Haber DA. Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. Cancer Res. 2007 Aug 1; 67(15):7319-26.
    View in: PubMed
  61. Haber DA, Settleman J. Cancer: drivers and passengers. Nature. 2007 Mar 8; 446(7132):145-6.
    View in: PubMed
  62. Mulloy R, Ferrand A, Kim Y, Sordella R, Bell DW, Haber DA, Anderson KS, Settleman J. Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res. 2007 Mar 1; 67(5):2325-30.
    View in: PubMed
  63. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007 Mar; 7(3):169-81.
    View in: PubMed
  64. Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol. 2007 Feb 10; 25(5):587-95.
    View in: PubMed
  65. Erkko H, Xia B, Nikkilä J, Schleutker J, Syrjäkoski K, Mannermaa A, Kallioniemi A, Pylkäs K, Karppinen SM, Rapakko K, Miron A, Sheng Q, Li G, Mattila H, Bell DW, Haber DA, Grip M, Reiman M, Jukkola-Vuorinen A, Mustonen A, Kere J, Aaltonen LA, Kosma VM, Kataja V, Soini Y, Drapkin RI, Livingston DM, Winqvist R. A recurrent mutation in PALB2 in Finnish cancer families. Nature. 2007 Mar 15; 446(7133):316-9.
    View in: PubMed
  66. Rivera MN, Kim WJ, Wells J, Driscoll DR, Brannigan BW, Han M, Kim JC, Feinberg AP, Gerald WL, Vargas SO, Chin L, Iafrate AJ, Bell DW, Haber DA. An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science. 2007 Feb 2; 315(5812):642-5.
    View in: PubMed
  67. Sequist LV, Joshi VA, Jänne PA, Muzikansky A, Fidias P, Meyerson M, Haber DA, Kucherlapati R, Johnson BE, Lynch TJ. Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist. 2007 Jan; 12(1):90-8.
    View in: PubMed
  68. Sharma SV, Gajowniczek P, Way IP, Lee DY, Jiang J, Yuza Y, Classon M, Haber DA, Settleman J. A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell. 2006 Nov; 10(5):425-35.
    View in: PubMed
  69. Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, Sgroi DC, Deng CX, Brugge JS, Haber DA. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A. 2006 Aug 15; 103(33):12405-10.
    View in: PubMed
  70. Sequist LV, Joshi VA, Jänne PA, Bell DW, Fidias P, Lindeman NI, Louis DN, Lee JC, Mark EJ, Longtine J, Verlander P, Kucherlapati R, Meyerson M, Haber DA, Johnson BE, Lynch TJ. Epidermal growth factor receptor mutation testing in the care of lung cancer patients. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 2):4403s-4408s.
    View in: PubMed
  71. Sharma SV, Fischbach MA, Haber DA, Settleman J. "Oncogenic shock": explaining oncogene addiction through differential signal attenuation. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 2):4392s-4395s.
    View in: PubMed
  72. Kwak EL, Jankowski J, Thayer SP, Lauwers GY, Brannigan BW, Harris PL, Okimoto RA, Haserlat SM, Driscoll DR, Ferry D, Muir B, Settleman J, Fuchs CS, Kulke MH, Ryan DP, Clark JW, Sgroi DC, Haber DA, Bell DW. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 1):4283-7.
    View in: PubMed
  73. Lynch TJ, Adjei AA, Bunn PA, Eisen TG, Engelman J, Goss GD, Haber DA, Heymach JV, Jänne PA, Johnson BE, Johnson DH, Lilenbaum RC, Meyerson M, Sandler AB, Sequist LV, Settleman J, Wong KK, Hart CS. Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 2):4365s-4371s.
    View in: PubMed
  74. Bell DW, Haber DA. A blood-based test for epidermal growth factor receptor mutations in lung cancer. Clin Cancer Res. 2006 Jul 1; 12(13):3875-7.
    View in: PubMed
  75. Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, Jänne PA. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 2006 Jul 1; 12(13):3908-14.
    View in: PubMed
  76. Diederichs S, Haber DA. Sequence variations of microRNAs in human cancer: alterations in predicted secondary structure do not affect processing. Cancer Res. 2006 Jun 15; 66(12):6097-104.
    View in: PubMed
  77. Smolen GA, Muir B, Mohapatra G, Barmettler A, Kim WJ, Rivera MN, Haserlat SM, Okimoto RA, Kwak E, Dahiya S, Garber JE, Bell DW, Sgroi DC, Chin L, Deng CX, Haber DA. Frequent met oncogene amplification in a Brca1/Trp53 mouse model of mammary tumorigenesis. Cancer Res. 2006 Apr 1; 66(7):3452-5.
    View in: PubMed
  78. Kwak EL, Kim S, Zhang J, Cardiff RD, Schmidt EV, Haber DA. Mammary tumorigenesis following transgenic expression of a dominant negative CHK2 mutant. Cancer Res. 2006 Feb 15; 66(4):1923-8.
    View in: PubMed
  79. Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H, Kim WJ, Okimoto RA, Bell DW, Sgroi DC, Christensen JG, Settleman J, Haber DA. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A. 2006 Feb 14; 103(7):2316-21.
    View in: PubMed
  80. Cohen EE, Lingen MW, Martin LE, Harris PL, Brannigan BW, Haserlat SM, Okimoto RA, Sgroi DC, Dahiya S, Muir B, Clark JR, Rocco JW, Vokes EE, Haber DA, Bell DW. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res. 2005 Nov 15; 11(22):8105-8.
    View in: PubMed
  81. Bell DW, Gore I, Okimoto RA, Godin-Heymann N, Sordella R, Mulloy R, Sharma SV, Brannigan BW, Mohapatra G, Settleman J, Haber DA. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet. 2005 Dec; 37(12):1315-6.
    View in: PubMed
  82. Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, Sgroi DC, Muir B, Riemenschneider MJ, Iacona RB, Krebs AD, Johnson DH, Giaccone G, Herbst RS, Manegold C, Fukuoka M, Kris MG, Baselga J, Ochs JS, Haber DA. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol. 2005 Nov 1; 23(31):8081-92.
    View in: PubMed
  83. Rivera MN, Haber DA. Wilms' tumour: connecting tumorigenesis and organ development in the kidney. Nat Rev Cancer. 2005 Sep; 5(9):699-712.
    View in: PubMed
  84. Haber DA, Settleman J. Overcoming acquired resistance to Iressa/Tarceva with inhibitors of a different class. Cell Cycle. 2005 Aug; 4(8):1057-9.
    View in: PubMed
  85. Sequist LV, Haber DA, Lynch TJ. Epidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors. Clin Cancer Res. 2005 Aug 15; 11(16):5668-70.
    View in: PubMed
  86. Lorenzen JA, Bonacci BB, Palmer RE, Wells C, Zhang J, Haber DA, Goldstein AM, Mayer AN. Rbm19 is a nucleolar protein expressed in crypt/progenitor cells of the intestinal epithelium. Gene Expr Patterns. 2005 Dec; 6(1):45-56.
    View in: PubMed
  87. Kwak EL, Moberg KH, Wahrer DC, Quinn JE, Gilmore PM, Graham CA, Hariharan IK, Harkin DP, Haber DA, Bell DW. Infrequent mutations of Archipelago (hAGO, hCDC4, Fbw7) in primary ovarian cancer. Gynecol Oncol. 2005 Jul; 98(1):124-8.
    View in: PubMed
  88. Gerald WL, Haber DA. The EWS-WT1 gene fusion in desmoplastic small round cell tumor. Semin Cancer Biol. 2005 Jun; 15(3):197-205.
    View in: PubMed
  89. Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, Harris PL, Driscoll DR, Fidias P, Lynch TJ, Rabindran SK, McGinnis JP, Wissner A, Sharma SV, Isselbacher KJ, Settleman J, Haber DA. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A. 2005 May 24; 102(21):7665-70.
    View in: PubMed
  90. Riemenschneider MJ, Bell DW, Haber DA, Louis DN. Pulmonary adenocarcinomas with mutant epidermal growth factor receptors. N Engl J Med. 2005 Apr 21; 352(16):1724-5.
    View in: PubMed
  91. Haber DA, Bell DW, Sordella R, Kwak EL, Godin-Heymann N, Sharma SV, Lynch TJ, Settleman J. Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. Cold Spring Harb Symp Quant Biol. 2005; 70:419-26.
    View in: PubMed
  92. Smolen GA, Vassileva MT, Wells J, Matunis MJ, Haber DA. SUMO-1 modification of the Wilms' tumor suppressor WT1. Cancer Res. 2004 Nov 1; 64(21):7846-51.
    View in: PubMed
  93. Sgroi DC, Haber DA, Ryan PD, Ma XJ, Erlander MG. RE: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell. 2004 Nov; 6(5):445.
    View in: PubMed
  94. Song YH, Mirey G, Betson M, Haber DA, Settleman J. The Drosophila ATM ortholog, dATM, mediates the response to ionizing radiation and to spontaneous DNA damage during development. Curr Biol. 2004 Aug 10; 14(15):1354-9.
    View in: PubMed
  95. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004 Aug 20; 305(5687):1163-7.
    View in: PubMed
  96. Zhang H, Christoforou A, Aravind L, Emmons SW, van den Heuvel S, Haber DA. The C. elegans Polycomb gene SOP-2 encodes an RNA binding protein. Mol Cell. 2004 Jun 18; 14(6):841-7.
    View in: PubMed
  97. Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, Muir B, Mohapatra G, Salunga R, Tuggle JT, Tran Y, Tran D, Tassin A, Amon P, Wang W, Wang W, Enright E, Stecker K, Estepa-Sabal E, Smith B, Younger J, Balis U, Michaelson J, Bhan A, Habin K, Baer TM, Brugge J, Haber DA, Erlander MG, Sgroi DC. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell. 2004 Jun; 5(6):607-16.
    View in: PubMed
  98. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004 May 20; 350(21):2129-39.
    View in: PubMed
  99. Zhang H, Smolen GA, Palmer R, Christoforou A, van den Heuvel S, Haber DA. SUMO modification is required for in vivo Hox gene regulation by the Caenorhabditis elegans Polycomb group protein SOP-2. Nat Genet. 2004 May; 36(5):507-11.
    View in: PubMed
  100. Gal I, Gershoni Baruch R, Haber D, Dagan E, Eisenberg-Barzilai S, Zidan J, Friedman E. The 1100delAT BRCA1 and the 8765delAG BRCA2 mutations: occurrence in high-risk non-Ashkenazi Jews and haplotype comparison of Jewish and non-Jewish carriers. Fam Cancer. 2004; 3(1):11-4.
    View in: PubMed
  101. Haber DA. The BRCA2-EMSY connection: implications for breast and ovarian tumorigenesis. Cell. 2003 Nov 26; 115(5):507-8.
    View in: PubMed
  102. Zhang H, Palmer R, Gao X, Kreidberg J, Gerald W, Hsiao L, Jensen RV, Gullans SR, Haber DA. Transcriptional activation of placental growth factor by the forkhead/winged helix transcription factor FoxD1. Curr Biol. 2003 Sep 16; 13(18):1625-9.
    View in: PubMed
  103. Ryan PD, Haber DA, Shannon KM, Smith BL, Fan MJ. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 28-2003. A 51-year-old premenopausal woman with newly diagnosed breast cancer and a strong family history of breast cancer. N Engl J Med. 2003 Sep 11; 349(11):1076-82.
    View in: PubMed
  104. Reynolds PA, Smolen GA, Palmer RE, Sgroi D, Yajnik V, Gerald WL, Haber DA. Identification of a DNA-binding site and transcriptional target for the EWS-WT1(+KTS) oncoprotein. Genes Dev. 2003 Sep 1; 17(17):2094-107.
    View in: PubMed
  105. Lee BC, Cheng T, Adams GB, Attar EC, Miura N, Lee SB, Saito Y, Olszak I, Dombkowski D, Olson DP, Hancock J, Choi PS, Haber DA, Luster AD, Scadden DT. P2Y-like receptor, GPR105 (P2Y14), identifies and mediates chemotaxis of bone-marrow hematopoietic stem cells. Genes Dev. 2003 Jul 1; 17(13):1592-604.
    View in: PubMed
  106. Hariharan IK, Haber DA. Yeast, flies, worms, and fish in the study of human disease. N Engl J Med. 2003 Jun 12; 348(24):2457-63.
    View in: PubMed
  107. Zhang H, Azevedo RB, Lints R, Doyle C, Teng Y, Haber D, Emmons SW. Global regulation of Hox gene expression in C. elegans by a SAM domain protein. Dev Cell. 2003 Jun; 4(6):903-15.
    View in: PubMed
  108. Yajnik V, Paulding C, Sordella R, McClatchey AI, Saito M, Wahrer DC, Reynolds P, Bell DW, Lake R, van den Heuvel S, Settleman J, Haber DA. DOCK4, a GTPase activator, is disrupted during tumorigenesis. Cell. 2003 Mar 7; 112(5):673-84.
    View in: PubMed
  109. Paulding CA, Ruvolo M, Haber DA. The Tre2 (USP6) oncogene is a hominoid-specific gene. Proc Natl Acad Sci U S A. 2003 Mar 4; 100(5):2507-11.
    View in: PubMed
  110. Varley J, Haber DA. Familial breast cancer and the hCHK2 1100delC mutation: assessing cancer risk. Breast Cancer Res. 2003; 5(3):123-5.
    View in: PubMed
  111. Palmer RE, Lee SB, Wong JC, Reynolds PA, Zhang H, Truong V, Oliner JD, Gerald WL, Haber DA. Induction of BAIAP3 by the EWS-WT1 chimeric fusion implicates regulated exocytosis in tumorigenesis. Cancer Cell. 2002 Dec; 2(6):497-505.
    View in: PubMed
  112. Ellisen LW, Ramsayer KD, Johannessen CM, Yang A, Beppu H, Minda K, Oliner JD, McKeon F, Haber DA. REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. Mol Cell. 2002 Nov; 10(5):995-1005.
    View in: PubMed
  113. Tapon N, Harvey KF, Bell DW, Wahrer DC, Schiripo TA, Haber D, Hariharan IK. salvador Promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines. Cell. 2002 Aug 23; 110(4):467-78.
    View in: PubMed
  114. Haber D. Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations. N Engl J Med. 2002 May 23; 346(21):1660-2.
    View in: PubMed
  115. Bell DW, Erban J, Sgroi DC, Haber DA. Selective loss of heterozygosity in multiple breast cancers from a carrier of mutations in both BRCA1 and BRCA2. Cancer Res. 2002 May 15; 62(10):2741-3.
    View in: PubMed
  116. Andrews HN, Mullan PB, McWilliams S, Sebelova S, Quinn JE, Gilmore PM, McCabe N, Pace A, Koller B, Johnston PG, Haber DA, Harkin DP. BRCA1 regulates the interferon gamma-mediated apoptotic response. J Biol Chem. 2002 Jul 19; 277(29):26225-32.
    View in: PubMed
  117. Wong JC, Lee SB, Bell MD, Reynolds PA, Fiore E, Stamenkovic I, Truong V, Oliner JD, Gerald WL, Haber DA. Induction of the interleukin-2/15 receptor beta-chain by the EWS-WT1 translocation product. Oncogene. 2002 Mar 27; 21(13):2009-19.
    View in: PubMed
  118. Ravenel JD, Broman KW, Perlman EJ, Niemitz EL, Jayawardena TM, Bell DW, Haber DA, Uejima H, Feinberg AP. Loss of imprinting of insulin-like growth factor-II (IGF2) gene in distinguishing specific biologic subtypes of Wilms tumor. J Natl Cancer Inst. 2001 Nov 21; 93(22):1698-703.
    View in: PubMed
  119. Lee SB, Kim SH, Bell DW, Wahrer DC, Schiripo TA, Jorczak MM, Sgroi DC, Garber JE, Li FP, Nichols KE, Varley JM, Godwin AK, Shannon KM, Harlow E, Haber DA. Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome. Cancer Res. 2001 Nov 15; 61(22):8062-7.
    View in: PubMed
  120. Palmer RE, Kotsianti A, Cadman B, Boyd T, Gerald W, Haber DA. WT1 regulates the expression of the major glomerular podocyte membrane protein Podocalyxin. Curr Biol. 2001 Nov 13; 11(22):1805-9.
    View in: PubMed
  121. Mullan PB, Quinn JE, Gilmore PM, McWilliams S, Andrews H, Gervin C, McCabe N, McKenna S, White P, Song YH, Maheswaran S, Liu E, Haber DA, Johnston PG, Harkin DP. BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene. 2001 Sep 27; 20(43):6123-31.
    View in: PubMed
  122. Moberg KH, Bell DW, Wahrer DC, Haber DA, Hariharan IK. Archipelago regulates Cyclin E levels in Drosophila and is mutated in human cancer cell lines. Nature. 2001 Sep 20; 413(6853):311-6.
    View in: PubMed
  123. Ellisen LW, Palmer RE, Maki RG, Truong VB, Tamayo P, Oliner JD, Haber DA. Cascades of transcriptional induction during human lymphocyte activation. Eur J Cell Biol. 2001 May; 80(5):321-8.
    View in: PubMed
  124. Ellisen LW, Carlesso N, Cheng T, Scadden DT, Haber DA. The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells. EMBO J. 2001 Apr 17; 20(8):1897-909.
    View in: PubMed
  125. Cantor SB, Bell DW, Ganesan S, Kass EM, Drapkin R, Grossman S, Wahrer DC, Sgroi DC, Lane WS, Haber DA, Livingston DM. BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell. 2001 Apr 6; 105(1):149-60.
    View in: PubMed
  126. Lee SB, Haber DA. Wilms tumor and the WT1 gene. Exp Cell Res. 2001 Mar 10; 264(1):74-99.
    View in: PubMed
  127. Arico M, Imashuku S, Clementi R, Hibi S, Teramura T, Danesino C, Haber DA, Nichols KE. Hemophagocytic lymphohistiocytosis due to germline mutations in SH2D1A, the X-linked lymphoproliferative disease gene. Blood. 2001 Feb 15; 97(4):1131-3.
    View in: PubMed
  128. Wang W, Lee SB, Palmer R, Ellisen LW, Haber DA. A functional interaction with CBP contributes to transcriptional activation by the Wilms tumor suppressor WT1. J Biol Chem. 2001 May 18; 276(20):16810-6.
    View in: PubMed
  129. Seth P, Lunetta KL, Bell DW, Gray H, Nasser SM, Rhei E, Kaelin CM, Iglehart DJ, Marks JR, Garber JE, Haber DA, Polyak K. Phenol sulfotransferases: hormonal regulation, polymorphism, and age of onset of breast cancer. Cancer Res. 2000 Dec 15; 60(24):6859-63.
    View in: PubMed
  130. Haber D. Roads leading to breast cancer. N Engl J Med. 2000 Nov 23; 343(21):1566-8.
    View in: PubMed
  131. Chaudhuri S, Cariappa A, Tang M, Bell D, Haber DA, Isselbacher KJ, Finkelstein D, Forcione D, Pillai S. Genetic susceptibility to breast cancer: HLA DQB*03032 and HLA DRB1*11 may represent protective alleles. Proc Natl Acad Sci U S A. 2000 Oct 10; 97(21):11451-4.
    View in: PubMed
  132. Ino Y, Wahrer DC, Bell DW, Haber DA, Louis DN. Mutation analysis of the hCHK2 gene in primary human malignant gliomas. Neurogenetics. 2000 Sep; 3(1):45-6.
    View in: PubMed
  133. Daniels GH, Haber DA. Will radioiodine be useful in treatment of breast cancer? Nat Med. 2000 Aug; 6(8):859-60.
    View in: PubMed
  134. Haber D. BRCA1: an emerging role in the cellular response to DNA damage. Lancet. 2000 Jun 17; 355(9221):2090-1.
    View in: PubMed
  135. Shafman TD, Levitz S, Nixon AJ, Gibans LA, Nichols KE, Bell DW, Ishioka C, Isselbacher KJ, Gelman R, Garber J, Harris JR, Haber DA. Prevalence of germline truncating mutations in ATM in women with a second breast cancer after radiation therapy for a contralateral tumor. Genes Chromosomes Cancer. 2000 Feb; 27(2):124-9.
    View in: PubMed
  136. Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch JM, Li FP, Garber JE, Haber DA. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science. 1999 Dec 24; 286(5449):2528-31.
    View in: PubMed
  137. Haber DA. Breast cancer in carriers of BRCA1 and BRCA2 mutations: tackling a molecular and clinical conundrum. J Clin Oncol. 1999 Nov; 17(11):3367-70.
    View in: PubMed
  138. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell. 1999 Oct 29; 99(3):247-57.
    View in: PubMed
  139. Celli J, Duijf P, Hamel BC, Bamshad M, Kramer B, Smits AP, Newbury-Ecob R, Hennekam RC, Van Buggenhout G, van Haeringen A, Woods CG, van Essen AJ, de Waal R, Vriend G, Haber DA, Yang A, McKeon F, Brunner HG, van Bokhoven H. Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome. Cell. 1999 Oct 15; 99(2):143-53.
    View in: PubMed
  140. Lee SB, Huang K, Palmer R, Truong VB, Herzlinger D, Kolquist KA, Wong J, Paulding C, Yoon SK, Gerald W, Oliner JD, Haber DA. The Wilms tumor suppressor WT1 encodes a transcriptional activator of amphiregulin. Cell. 1999 Sep 3; 98(5):663-73.
    View in: PubMed
  141. Bell DW, Wahrer DC, Kang DH, MacMahon MS, FitzGerald MG, Ishioka C, Isselbacher KJ, Krainer M, Haber DA. Common nonsense mutations in RAD52. Cancer Res. 1999 Aug 15; 59(16):3883-8.
    View in: PubMed
  142. Harkin DP, Bean JM, Miklos D, Song YH, Truong VB, Englert C, Christians FC, Ellisen LW, Maheswaran S, Oliner JD, Haber DA. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell. 1999 May 28; 97(5):575-86.
    View in: PubMed
  143. Nichols KE, Levitz S, Shannon KE, Wahrer DC, Bell DW, Chang G, Hegde S, Neuberg D, Shafman T, Tarbell NJ, Mauch P, Ishioka C, Haber DA, Diller L. Heterozygous germline ATM mutations do not contribute to radiation-associated malignancies after Hodgkin's disease. J Clin Oncol. 1999 Apr; 17(4):1259.
    View in: PubMed
  144. O'Donnell L, Stueve A, San Doval A, Duran R, Haber D, Atnafou R, Johnson N, Grant U, Murray H, Juhn G, Tang J, Piessens P. The effectiveness of the Reach for Health Community Youth Service learning program in reducing early and unprotected sex among urban middle school students. Am J Public Health. 1999 Feb; 89(2):176-81.
    View in: PubMed
  145. O'Donnell L, Stueve A, San Doval A, Duran R, Atnafou R, Haber D, Johnson N, Murray H, Grant U, Juhn G, Tang J, Bass J, Piessens P. Violence prevention and young adolescents' participation in community youth service. J Adolesc Health. 1999 Jan; 24(1):28-37.
    View in: PubMed
  146. Nichols KE, Harkin DP, Levitz S, Krainer M, Kolquist KA, Genovese C, Bernard A, Ferguson M, Zuo L, Snyder E, Buckler AJ, Wise C, Ashley J, Lovett M, Valentine MB, Look AT, Gerald W, Housman DE, Haber DA. Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc Natl Acad Sci U S A. 1998 Nov 10; 95(23):13765-70.
    View in: PubMed
  147. FitzGerald MG, Marsh DJ, Wahrer D, Bell D, Caron S, Shannon KE, Ishioka C, Isselbacher KJ, Garber JE, Eng C, Haber DA. Germline mutations in PTEN are an infrequent cause of genetic predisposition to breast cancer. Oncogene. 1998 Aug 13; 17(6):727-31.
    View in: PubMed
  148. Kolquist KA, Ellisen LW, Counter CM, Meyerson M, Tan LK, Weinberg RA, Haber DA, Gerald WL. Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nat Genet. 1998 Jun; 19(2):182-6.
    View in: PubMed
  149. Dahia PL, FitzGerald MG, Zhang X, Marsh DJ, Zheng Z, Pietsch T, von Deimling A, Haluska FG, Haber DA, Eng C. A highly conserved processed PTEN pseudogene is located on chromosome band 9p21. Oncogene. 1998 May 7; 16(18):2403-6.
    View in: PubMed
  150. Haber DA, Fearon ER. The promise of cancer genetics. Lancet. 1998 May; 351 Suppl 2:SII1-8.
    View in: PubMed
  151. Maheswaran S, Englert C, Lee SB, Ezzel RM, Settleman J, Haber DA. E1B 55K sequesters WT1 along with p53 within a cytoplasmic body in adenovirus-transformed kidney cells. Oncogene. 1998 Apr 23; 16(16):2041-50.
    View in: PubMed
  152. Maheswaran S, Englert C, Zheng G, Lee SB, Wong J, Harkin DP, Bean J, Ezzell R, Garvin AJ, McCluskey RT, DeCaprio JA, Haber DA. Inhibition of cellular proliferation by the Wilms tumor suppressor WT1 requires association with the inducible chaperone Hsp70. Genes Dev. 1998 Apr 15; 12(8):1108-20.
    View in: PubMed
  153. Counter CM, Meyerson M, Eaton EN, Ellisen LW, Caddle SD, Haber DA, Weinberg RA. Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene. 1998 Mar 5; 16(9):1217-22.
    View in: PubMed
  154. Nichols KE, Li FP, Haber DA, Diller L. Childhood cancer predisposition: applications of molecular testing and future implications. J Pediatr. 1998 Mar; 132(3 Pt 1):389-97.
    View in: PubMed
  155. Ellisen LW, Haber DA. Hereditary breast cancer. Annu Rev Med. 1998; 49:425-36.
    View in: PubMed
  156. Pollock PM, Spurr N, Bishop T, Newton-Bishop J, Gruis N, van der Velden PA, Goldstein AM, Tucker MA, Foulkes WD, Barnhill R, Haber D, Fountain J, Hayward NK. Haplotype analysis of two recurrent CDKN2A mutations in 10 melanoma families: evidence for common founders and independent mutations. Hum Mutat. 1998; 11(6):424-31.
    View in: PubMed
  157. Haber DA. Splicing into senescence: the curious case of p16 and p19ARF. Cell. 1997 Nov 28; 91(5):555-8.
    View in: PubMed
  158. Lee SB, Kolquist KA, Nichols K, Englert C, Maheswaran S, Ladanyi M, Gerald WL, Haber DA. The EWS-WT1 translocation product induces PDGFA in desmoplastic small round-cell tumour. Nat Genet. 1997 Nov; 17(3):309-13.
    View in: PubMed
  159. Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, Ziaugra L, Beijersbergen RL, Davidoff MJ, Liu Q, Bacchetti S, Haber DA, Weinberg RA. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell. 1997 Aug 22; 90(4):785-95.
    View in: PubMed
  160. Haber D, Harlow E. Tumour-suppressor genes: evolving definitions in the genomic age. Nat Genet. 1997 Aug; 16(4):320-2.
    View in: PubMed
  161. Krainer M, Silva-Arrieta S, FitzGerald MG, Shimada A, Ishioka C, Kanamaru R, MacDonald DJ, Unsal H, Finkelstein DM, Bowcock A, Isselbacher KJ, Haber DA. Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. N Engl J Med. 1997 May 15; 336(20):1416-21.
    View in: PubMed
  162. Englert C, Maheswaran S, Garvin AJ, Kreidberg J, Haber DA. Induction of p21 by the Wilms' tumor suppressor gene WT1. Cancer Res. 1997 Apr 15; 57(8):1429-34.
    View in: PubMed
  163. Ishioka C, Suzuki T, FitzGerald M, Krainer M, Shimodaira H, Shimada A, Nomizu T, Isselbacher KJ, Haber D, Kanamaru R. Detection of heterozygous truncating mutations in the BRCA1 and APC genes by using a rapid screening assay in yeast. Proc Natl Acad Sci U S A. 1997 Mar 18; 94(6):2449-53.
    View in: PubMed
  164. FitzGerald MG, Bean JM, Hegde SR, Unsal H, MacDonald DJ, Harkin DP, Finkelstein DM, Isselbacher KJ, Haber DA. Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet. 1997 Mar; 15(3):307-10.
    View in: PubMed
  165. Johnstone RW, See RH, Sells SF, Wang J, Muthukkumar S, Englert C, Haber DA, Licht JD, Sugrue SP, Roberts T, Rangnekar VM, Shi Y. A novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1. Mol Cell Biol. 1996 Dec; 16(12):6945-56.
    View in: PubMed
  166. Haber DA, Englert C, Maheswaran S. Functional properties of WT1. Med Pediatr Oncol. 1996 Nov; 27(5):453-5.
    View in: PubMed
  167. Tonin P, Weber B, Offit K, Couch F, Rebbeck TR, Neuhausen S, Godwin AK, Daly M, Wagner-Costalos J, Berman D, Grana G, Fox E, Kane MF, Kolodner RD, Krainer M, Haber DA, Struewing JP, Warner E, Rosen B, Lerman C, Peshkin B, Norton L, Serova O, Foulkes WD, Garber JE, et al. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med. 1996 Nov; 2(11):1179-83.
    View in: PubMed
  168. FitzGerald MG, Harkin DP, Silva-Arrieta S, MacDonald DJ, Lucchina LC, Unsal H, O'Neill E, Koh J, Finkelstein DM, Isselbacher KJ, Sober AJ, Haber DA. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc Natl Acad Sci U S A. 1996 Aug 6; 93(16):8541-5.
    View in: PubMed
  169. FitzGerald MG, MacDonald DJ, Krainer M, Hoover I, O'Neil E, Unsal H, Silva-Arrieto S, Finkelstein DM, Beer-Romero P, Englert C, Sgroi DC, Smith BL, Younger JW, Garber JE, Duda RB, Mayzel KA, Isselbacher KJ, Friend SH, Haber DA. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med. 1996 Jan 18; 334(3):143-9.
    View in: PubMed
  170. Lamartine J, Nichols KE, Yin L, Krainer M, Heitzmann F, Bernard A, Gaudi S, Lenoir GM, Sullivan JL, Ikeda JE, Porta G, Schlessinger D, Romeo G, Haber DA, Sylla BS, Harkin DP. Physical map and cosmid contig encompassing a new interstitial deletion of the X-linked lymphoproliferative syndrome region. Eur J Hum Genet. 1996; 4(6):342-51.
    View in: PubMed
  171. Englert C, Vidal M, Maheswaran S, Ge Y, Ezzell RM, Isselbacher KJ, Haber DA. Truncated WT1 mutants alter the subnuclear localization of the wild-type protein. Proc Natl Acad Sci U S A. 1995 Dec 19; 92(26):11960-4.
    View in: PubMed
  172. Grundy P, Coppes MJ, Haber D. Molecular genetics of Wilms tumor. Hematol Oncol Clin North Am. 1995 Dec; 9(6):1201-15.
    View in: PubMed
  173. Nichols KE, Re GG, Yan YX, Garvin AJ, Haber DA. WT1 induces expression of insulin-like growth factor 2 in Wilms' tumor cells. Cancer Res. 1995 Oct 15; 55(20):4540-3.
    View in: PubMed
  174. Englert C, Hou X, Maheswaran S, Bennett P, Ngwu C, Re GG, Garvin AJ, Rosner MR, Haber DA. WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis. EMBO J. 1995 Oct 2; 14(19):4662-75.
    View in: PubMed
  175. Maheswaran S, Englert C, Bennett P, Heinrich G, Haber DA. The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. Genes Dev. 1995 Sep 1; 9(17):2143-56.
    View in: PubMed
  176. Luo XN, Reddy JC, Yeyati PL, Idris AH, Hosono S, Haber DA, Licht JD, Atweh GF. The tumor suppressor gene WT1 inhibits ras-mediated transformation. Oncogene. 1995 Aug 17; 11(4):743-50.
    View in: PubMed
  177. Reddy JC, Morris JC, Wang J, English MA, Haber DA, Shi Y, Licht JD. WT1-mediated transcriptional activation is inhibited by dominant negative mutant proteins. J Biol Chem. 1995 May 5; 270(18):10878-84.
    View in: PubMed
  178. Haber DA. Telomeres, cancer, and immortality. N Engl J Med. 1995 Apr 6; 332(14):955-6.
    View in: PubMed
  179. Coppes MJ, Haber DA, Grundy PE. Genetic events in the development of Wilms' tumor. N Engl J Med. 1994 Sep 1; 331(9):586-90.
    View in: PubMed
  180. Weremowicz S, Kozakewich HP, Haber D, Park S, Morton CC, Fletcher JA. Identification of genetically aberrant cell lineages in Wilms' tumors. Genes Chromosomes Cancer. 1994 May; 10(1):40-8.
    View in: PubMed
  181. Haber DA, Park S, Maheswaran S, Englert C, Re GG, Hazen-Martin DJ, Sens DA, Garvin AJ. WT1-mediated growth suppression of Wilms tumor cells expressing a WT1 splicing variant. Science. 1993 Dec 24; 262(5142):2057-9.
    View in: PubMed
  182. Park S, Bernard A, Bove KE, Sens DA, Hazen-Martin DJ, Garvin AJ, Haber DA. Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour. Nat Genet. 1993 Dec; 5(4):363-7.
    View in: PubMed
  183. Park S, Tomlinson G, Nisen P, Haber DA. Altered trans-activational properties of a mutated WT1 gene product in a WAGR-associated Wilms' tumor. Cancer Res. 1993 Oct 15; 53(20):4757-60.
    View in: PubMed
  184. Maheswaran S, Park S, Bernard A, Morris JF, Rauscher FJ, Hill DE, Haber DA. Physical and functional interaction between WT1 and p53 proteins. Proc Natl Acad Sci U S A. 1993 Jun 1; 90(11):5100-4.
    View in: PubMed
  185. Roberts DJ, Haber D, Sklar J, Crum CP. Extrarenal Wilms' tumors. A study of their relationship with classical renal Wilms' tumor using expression of WT1 as a molecular marker. Lab Invest. 1993 May; 68(5):528-36.
    View in: PubMed
  186. Skare J, Wu BL, Madan S, Pulijaal V, Purtilo D, Haber D, Nelson D, Sylla B, Grierson H, Nitowsky H, et al. Characterization of three overlapping deletions causing X-linked lymphoproliferative disease. Genomics. 1993 Apr; 16(1):254-5.
    View in: PubMed
  187. Baird PN, Groves N, Haber DA, Housman DE, Cowell JK. Identification of mutations in the WT1 gene in tumours from patients with the WAGR syndrome. Oncogene. 1992 Nov; 7(11):2141-9.
    View in: PubMed
  188. Haber DA, Timmers HT, Pelletier J, Sharp PA, Housman DE. A dominant mutation in the Wilms tumor gene WT1 cooperates with the viral oncogene E1A in transformation of primary kidney cells. Proc Natl Acad Sci U S A. 1992 Jul 1; 89(13):6010-4.
    View in: PubMed
  189. Haber DA, Buckler AJ. WT1: a novel tumor suppressor gene inactivated in Wilms' tumor. New Biol. 1992 Feb; 4(2):97-106.
    View in: PubMed
  190. Haber DA. Multidrug resistance (MDR 1) in leukemia: is it time to test? Blood. 1992 Jan 15; 79(2):295-8.
    View in: PubMed
  191. Haber DA, Housman DE. Role of the WT1 gene in Wilms' tumour. Cancer Surv. 1992; 12:105-17.
    View in: PubMed
  192. Haber DA, Housman DE. The genetics of Wilms' tumor. Adv Cancer Res. 1992; 59:41-68.
    View in: PubMed
  193. Haber DA, Sohn RL, Buckler AJ, Pelletier J, Call KM, Housman DE. Alternative splicing and genomic structure of the Wilms tumor gene WT1. Proc Natl Acad Sci U S A. 1991 Nov 1; 88(21):9618-22.
    View in: PubMed
  194. Grundy P, Telzerow P, Paterson MC, Haber D, Berman B, Li F, Garber J. Chromosome 11 uniparental isodisomy predisposing to embryonal neoplasms. Lancet. 1991 Oct 26; 338(8774):1079-80.
    View in: PubMed
  195. Pelletier J, Bruening W, Li FP, Haber DA, Glaser T, Housman DE. WT1 mutations contribute to abnormal genital system development and hereditary Wilms' tumour. Nature. 1991 Oct 3; 353(6343):431-4.
    View in: PubMed
  196. Pelletier J, Schalling M, Buckler AJ, Rogers A, Haber DA, Housman D. Expression of the Wilms' tumor gene WT1 in the murine urogenital system. Genes Dev. 1991 Aug; 5(8):1345-56.
    View in: PubMed
  197. Schwartz CE, Haber DA, Stanton VP, Strong LC, Skolnick MH, Housman DE. Familial predisposition to Wilms tumor does not segregate with the WT1 gene. Genomics. 1991 Aug; 10(4):927-30.
    View in: PubMed
  198. Huff V, Miwa H, Haber DA, Call KM, Housman D, Strong LC, Saunders GF. Evidence for WT1 as a Wilms tumor (WT) gene: intragenic germinal deletion in bilateral WT. Am J Hum Genet. 1991 May; 48(5):997-1003.
    View in: PubMed
  199. Buckler AJ, Chang DD, Graw SL, Brook JD, Haber DA, Sharp PA, Housman DE. Exon amplification: a strategy to isolate mammalian genes based on RNA splicing. Proc Natl Acad Sci U S A. 1991 May 1; 88(9):4005-9.
    View in: PubMed
  200. Cowell JK, Wadey RB, Haber DA, Call KM, Housman DE, Pritchard J. Structural rearrangements of the WT1 gene in Wilms' tumour cells. Oncogene. 1991 Apr; 6(4):595-9.
    View in: PubMed
  201. Buckler AJ, Pelletier J, Haber DA, Glaser T, Housman DE. Isolation, characterization, and expression of the murine Wilms' tumor gene (WT1) during kidney development. Mol Cell Biol. 1991 Mar; 11(3):1707-12.
    View in: PubMed
  202. Haber DA, Housman DE. Rate-limiting steps: the genetics of pediatric cancers. Cell. 1991 Jan 11; 64(1):5-8.
    View in: PubMed
  203. Haber DA, Buckler AJ, Glaser T, Call KM, Pelletier J, Sohn RL, Douglass EC, Housman DE. An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor. Cell. 1990 Jun 29; 61(7):1257-69.
    View in: PubMed
  204. Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA, Rose EA, Kral A, Yeger H, Lewis WH, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell. 1990 Feb 9; 60(3):509-20.
    View in: PubMed
  205. Haber DA, Housman DE. MspI/HpaII polymorphism in the human multidrug resistance gene 1. Nucleic Acids Res. 1989 Dec 11; 17(23):10142.
    View in: PubMed
  206. Croop JM, Raymond M, Haber D, Devault A, Arceci RJ, Gros P, Housman DE. The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol. 1989 Mar; 9(3):1346-50.
    View in: PubMed
  207. Darzynkiewicz E, Stepinski J, Ekiel I, Jin Y, Haber D, Sijuwade T, Tahara SM. Beta-globin mRNAs capped with m7G, m2.7(2)G or m2.2.7(3)G differ in intrinsic translation efficiency. Nucleic Acids Res. 1988 Sep 26; 16(18):8953-62.
    View in: PubMed
  208. Haber DA, Mayer RJ. Primary gastrointestinal lymphoma. Semin Oncol. 1988 Apr; 15(2):154-69.
    View in: PubMed
  209. Haber D. Yoga as a preventive health care program for white and black elders: an exploratory study. Int J Aging Hum Dev. 1983; 17(3):169-76.
    View in: PubMed
  210. Haber DA, Schimke RT. Unstable amplification of an altered dihydrofolate reductase gene associated with double-minute chromosomes. Cell. 1981 Nov; 26(3 Pt 1):355-62.
    View in: PubMed
  211. Haber DA, Fox DA, Dynan WS, Thilly WG. Cell density dependence of focus formation in the C3H/10T1/2 transformation assay. Cancer Res. 1977 Jun; 37(6):1644-8.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Haber's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_